Molecular cancer therapeutics
Journal
Overview
publication venue for
-
Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis.
2021
-
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
2010
-
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)..
22.
2023
-
Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms.
2022
-
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma..
21.
2022
-
Noninvasive Imaging of CD4+ T Cells in Humanized Mice..
21.
2022
-
Intraperitoneal pretargeted radioimmunotherapy for colorectal peritoneal carcinomatosis.
2021
-
ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma..
20.
2021
-
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma..
20.
2021
-
A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis..
19.
2020
-
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy..
19.
2020
-
Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells..
19.
2020
-
Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer..
19.
2020
-
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy..
19.
2020
-
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma..
19.
2019
-
Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes..
18.
2019
-
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis..
18.
2019
-
Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis..
18.
2019
-
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers..
17.
2018
-
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer..
17.
2018
-
Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation..
17.
2018
-
A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response..
17.
2018
-
AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth..
17.
2017
-
A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib..
16.
2017
-
HPMA-Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer..
16.
2017
-
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma..
16.
2017
-
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis..
16.
2017
-
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer..
16.
2017
-
Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry..
16.
2016
-
Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study..
15.
2016
-
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors..
15.
2016
-
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts..
15.
2016
-
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team..
14.
2015
-
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans..
14.
2015
-
ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells..
14.
2015
-
MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma..
14.
2014
-
Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling..
14.
2014
-
Repurposing the antihelmintic mebendazole as a hedgehog inhibitor..
14.
2014
-
Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer..
13.
2014
-
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD..
13.
2014
-
BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine..
13.
2014
-
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex..
13.
2014
-
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia..
13.
2014
-
Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling..
13.
2014
-
In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome..
12.
2013
-
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer..
12.
2013
-
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States..
12.
2013
-
ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer..
12.
2013
-
Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death..
12.
2013
-
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics..
12.
2013
-
Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo..
12.
2013
-
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer..
11.
2012
-
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component..
11.
2012
-
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models..
11.
2012
-
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells..
11.
2012
-
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells..
11.
2012
-
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers..
11.
2011
-
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling..
11.
2011
-
A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists..
11.
2011
-
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer..
10.
2011
-
Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes..
10.
2011
-
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo..
10.
2010
-
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma..
9.
2010
-
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer..
9.
2010
-
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model..
9.
2010
-
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer..
9.
2010
-
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38..
9.
2010
-
Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature..
9.
2010
-
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib..
9.
2010
-
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer..
9.
2010
-
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance..
8.
2009
-
Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells..
8.
2009
-
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts..
8.
2009
-
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model..
8.
2009
-
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development..
8.
2009
-
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells..
7.
2008
-
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer..
7.
2008
-
Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor..
7.
2008
-
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells..
7.
2008
-
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells..
7.
2008
-
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells..
7.
2008
-
Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model..
6.
2007
-
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib..
6.
2007
-
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer..
6.
2007
-
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function..
6.
2007
-
Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors..
6.
2007
-
The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma..
6.
2007
-
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460..
6.
2007
-
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer..
6.
2007
-
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays..
6.
2007
-
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation..
6.
2007
-
Assessment of celecoxib pharmacodynamics in pancreatic cancer..
5.
2006
-
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients..
5.
2006
-
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen..
5.
2006
-
A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity..
5.
2006
-
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T..
5.
2006
-
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration..
5.
2006
-
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine..
5.
2006
-
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers..
4.
2005
-
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy..
4.
2005
-
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells..
4.
2005
-
Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin..
3.
2004
-
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations..
3.
2004
-
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer..
3.
2004
-
A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra..
2.
2003
-
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis..
2.
2003
-
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma..
2.
2003
-
17AAG: low target binding affinity and potent cell activity--finding an explanation..
2.
2003
-
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines..
1.
2002
-
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity..
1.
2002
-
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma..
1.
2002
-
Efficacy of zibotentan in colorectal cancer--letter.
2014
-
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
2006
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)